Vanda Pharmaceuticals Reports Q1 2026 Earnings
Vanda Pharmaceuticals (VNDA) reported Q1 2026 earnings with mixed results across its product lines. Total net product sales were $51.7 million, up 3% year-over-year but down 10% from the prior quarter. Fanapt showed strong prescription growth, while Hetlioz and Ponvory faced challenges from generic competition and seasonal factors.
Topics: financial_results net_loss pharmaceuticals product_sales